Recent developments in the therapy of acromegaly

Expert Opinion on Investigational Drugs

Volumn 15, Issue 3, 2006, Pages 251-256

  Paisley, Angela N ^a   Trainer, Peter J ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Acromegaly; Growth hormone; Insulin like growth factor 1

Indexed keywords

ANGIOPEPTIN; ATL 1103; ATRIGEL; BIM 23197; BIM 23244; BIM 23268; BIM 23A387; BROMOCRIPTINE; CABERGOLINE; COMPLEMENTARY RNA; DOPAMINE RECEPTOR STIMULATING AGENT; GROWTH HORMONE; LANREOTIDE AUTOGEL; OCTREOTIDE; PASIREOTIDE; PEGVISOMANT; PERGOLIDE; QUINAGOLIDE; SANDOSTATIN LAR DEPOT; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; SOMATULINE SR; UNCLASSIFIED DRUG; VP 003;

ACROMEGALY; BENIGN TUMOR; CLINICAL FEATURE; CLINICAL TRIAL; DIABETES MELLITUS; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG STRUCTURE; GROWTH HORMONE RELEASE; HUMAN; HYPOPHYSIS ADENOMA; HYPOPHYSIS TUMOR; IMPAIRED GLUCOSE TOLERANCE; LIFE EXPECTANCY; MORBIDITY; MORTALITY; NONHUMAN; REVIEW; TREATMENT OUTCOME;

ACROMEGALY; HORMONE ANTAGONISTS; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I;

EID: 33644762047     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.15.3.251     Document Type: Review

References (41)

1. PRADHANANGA S, WILKINSON I, ROSS RJ: Pegvisomant: structure and function. J. Mol. Endocrinol. (2002) 29(1):11-14.
2. HOLDAWAY IM, RAJASOORYA C: Epidemiology of acromegaly. Pituitary (1999) 2(1):29-41.
3. GIUSTINA A, BARKAN A, CASANUEVA FF et al.: Criteria for cure of acromegaly: a consensus statement. J. Clin. Endocrinol. Metab. (2000) 85(2):526-529.
4. EZZAT S, FORSTER MJ, BERCHTOLD P et al.: Acromegaly. Clinical and biochemical features in 500 patients. Medicine (Baltimore) (1994) 73(5):233-240.
5. SERRI O, BEAUREGARD C, HARDY J: Long-term biochemical status and disease-related morbidity in 53 postoperative patients with acromegaly. J. Clin. Endocrinol. Metab. (2004) 89(2):658-661.
6. COLAO A, VITALE G, PIVONELLO R et al.: The heart: an end-organ of GH action. Eur. J. Endocrinol. (2004) 151(Suppl. 1):S93-S101.
7. RAJASOORYA C, HOLDAWAY IM, WRIGHTSON P, SCOTT DJ, IBBERTSON HK: Determinants of clinical outcome and survival in acromegaly. Clin. Endocrinol. (Oxf.) (1994) 41(1):95-102.
8. BATES AS, VAN'T HOFF W, JONES JM, CLAYTON RN: An audit of outcome of treatment in acromegaly. Q. J. Med. (1993) 86(5):293-299.
9. HOLDAWAY IM, RAJASOORYA RC, GAMBLE GD: Factors influencing mortality in acromegaly. J. Clin. Endocrinol. Metab. (2004) 89(2):667-674.
10. ORME SM, McNALLY RJ, CARTWRIGHT RA, BELCHETZ PE: Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J. Clin. Endocrinol. Metab. (1998) 83(8):2730-2734.
11. SWEARINGEN B, BARKER FG II, KATZNELSON L et al: Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J. Clin. Endocrinol. Metab. (1998) 83(10):3419-3426.
12. TRAINER PJ: Editorial: acromegaly-consensus, what consensus? J. Clin. Endocrinol. Metab. (2002) 87(8):3534-3536.
13. FREDA PU, WARDLAW SL, POST KD: Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly. J. Neurosurg. (1998) 89(3):353-358.
14. SHEAVES R, JENKINS P, BLACKBURN P et al.: Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure. Clin. Endocrinol. (Oxf.) (1996) 45(4):407-413.
15. ERFURTH EM, BULOW B, HAGMAR LE: Is vascular mortality increased in hypopituitarism? Pituitary (2000) 3(2):77-81.
16. JAFFE CA, BARKAN AL: Treatment of acromegaly with dopamine agonists. Endocrinol. Metab. Clin. North Am. (1992) 21(3):713-735.
17. ABS R, VERHELST J, MAITER D et al.: Cabergoline in the treatment of acromegaly: a study in 64 patients. J. Clin. Endocrinol. Metab. (1998) 83(2):374-378.
18. FERONE D, PIVONELLO R, LASTORIA S et al.: In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy. Clin. Endocrinol. (Oxf.) (2001) 54(4):469-477.
19. KENDALL-TAYLOR P, UPSTILL-GODDARD G, COOK D: Longterm pergolide treatment of acromegaly. Clin. Endocrinol. (Oxf.) (1983) 19(6):711-719.
20. BEVAN JS, ATKIN SL, ATKINSON AB et al.: Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J. Clin. Endocrinol. Metab. (2002) 87(10):4554-4563.
21. COLAO, A, FERONE D, MARZULLO P et al.: Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J. Clin. Endocrinol. Metab. (2001) 86(6):2779-2786.
22. FREDA PU: Somatostatin analogs in acromegaly. J. Clin. Endocrinol. Metab. (2002) 87(7):3013-3018.
23. AYUK J, STEWART SE, STEWART PM, SHEPPARD MC: Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly. J. Clin. Endocrinol. Metab. (2002) 87(9):4142-4146.
24. VAN DER LELY AJ, HUTSON RK, TRAINER PJ et al.: Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet (2001) 358(9295):1754-1759.
25. BESSER GM, BURMAN P, DALY AF: Predictors and rates of treatment-resistant tumor growth in acromegaly. Eur. J. Endocrinol. (2005) 153(2):187-193.
26. PATEL YC: Somatostatin and its receptor family. Front. Neuroendocrinol. (1999) 20(3):157-198.
27. MILLER GM, ALEXANDER JM, BIKKAL HA et al.: Somatostatin receptor subtype gene expression in pituitary adenomas. J. Clin. Endocrinol. Metab. (1995) 80(4):1386-1392.
28. GREENMAN Y, MELMED S: Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors. J. Clin. Endocrinol. Metab. (1994) 78(2):398-403.
29. REISINE T, BELL GI: Molecular biology of somatostatin receptors. Endocr. Rev. (1995) 16(4):427-442.
30. SHIMON I, TAYLOR JE, DONG JZ et al.: Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation. J. Clin. Invest. (1997) 99(4):789-798.
31. SHIMON I, YAN X, TAYLOR JE et al.: Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. J. Clin. Invest. (1997) 100(9):2386-2392.
32. ROHRER SP, BIRZIN ET, MOSLEY RT et al.: Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science (1998) 282(5389):737-740.
33. LAMBERTS SW, VAN DER LELY AJ, HOFLAND LJ: New somatostatin analogs: will they fulfil old promises? Eur. J. Endocrinol. (2002) 146(5):701-705.
34. JAQUET P, SAVEANU A, GUNZ G et al.: Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes. J. Clin. Endocrinol. Metab. (2000) 85(2):781-792.
35. STROWSKI MZ, KOHLER M, CHEN HY et al.: Somatostatin receptor subtype 5 regulates insulin secretion and glucose homeostasis. Mol. Endocrinol. (2003) 17(1):93-106.
36. MELMED S, STERNBERG R, COOK D et al.: A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin. Endocrinol. Metab (2005) 90(7):4405-4410.
37. BRUNS C, LEWIS I, BRINER U, MENO-TETANG G, WECKBECKER G: SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur. J. Endocrinol. (2002) 146(5):707-716.
38. VAN DER HOEK J, DE HERDER WW, FEELDERS RA et al.: A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients. J. Clin. Endocrinol. Metab. (2004) 89(2):638-645.
39. SAVEANU A, GUNZ G, DUFOUR H et al.: Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas. J. Clin. Endocrinol. Metab. (2001) 86(1):140-145.
40. ROCHEVILLE M, LANGE DC, KUMAR U et al.: Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science (2000) 288(5463):154-157.
41. SAVEANU A, LAVAQUE E, GUNZ G et al.: Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells. J. Clin. Endocrinol. Metab. (2002) 87(12):5545-5552.